Abstract
A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Current Radiopharmaceuticals
Title:A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation
Volume: 6 Issue: 1
Author(s): Ling Qiu, Wen Cheng, Jianguo Lin, Shu Zhang and Shineng Luo
Affiliation:
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Abstract: A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Export Options
About this article
Cite this article as:
Qiu Ling, Cheng Wen, Lin Jianguo, Zhang Shu and Luo Shineng, A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation, Current Radiopharmaceuticals 2013; 6 (1) . https://dx.doi.org/10.2174/1874471011306010005
DOI https://dx.doi.org/10.2174/1874471011306010005 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety
Recent Patents on Anti-Cancer Drug Discovery Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Perinatal Management of Fetal Tumors
Current Pediatric Reviews Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry Radiolabelling of Ascorbic Acid: A New Clue to Clarify its Action as an Anticancer Agent?
Current Radiopharmaceuticals Single-cell Sequencing in the Field of Stem Cells
Current Genomics Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Fentanyl for Breakthrough Cancer Pain: Where are We?
Reviews on Recent Clinical Trials